Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
Actuate Therapeutics Inc.
Inhibrx Biosciences, Inc
Tyligand Pharmaceuticals (Suzhou) Limited
University of Kentucky
Merck Sharp & Dohme LLC
Trishula Therapeutics, Inc.
Merck Sharp & Dohme LLC
German Cancer Research Center
Eastern Cooperative Oncology Group
Grupo Espanol de Investigacion en Sarcomas
Scandion Oncology A/S
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
UConn Health
M.D. Anderson Cancer Center
University of California, San Francisco